Researchers have successfully applied exome sequencing to discover causal variants in selected individuals with familial, highly penetrant disorders. We demonstrate the utility of exome sequencing followed by imputation for discovering low-frequency variants associated with complex quantitative traits. We performed exome sequencing in a reference panel of 761 African Americans and then imputed newly discovered variants into a larger sample of more than 13,000 African Americans for association testing with the blood cell traits hemoglobin, hematocrit, white blood count, and platelet count. First, we illustrate the feasibility of our approach by demonstrating genome-wide-significant associations for variants that are not covered by conventional genotyping arrays; for example, one such association is that between higher platelet count and an MPL c.117G>T (p.Lys39Asn) variant encoding a p.Lys39Asn amino acid substitution of the thrombpoietin receptor gene (p ¼ 1.5 3 10
Introduction
Blood cell counts are heritable traits that represent important intermediate phenotypes for a variety of cardiovascular, hematologic, oncologic, immunologic, and infectious diseases. Traits such as hemoglobin and leukocyte or white blood cell count (WBC) are known to differ by ancestry. Through admixture mapping, the DARC null allele has been identified as a major determinant of the lower WBC in African-descended individuals as compared with European Americans.
1 Recent genome-wide association studies (GWASs) have further contributed to our understanding of the variability of blood cell traits both within and across European-, African-, and Asiandescended populations. For example, the CHARGE, CARe, COGENT, and HaemGen consortia have identified~100
loci associated with blood cell traits, including hemoglobin concentration, hematocrit, red blood cell indices, WBC, platelet count, and mean platelet volume (MPV).
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Lower-frequency or population-specific variants that are not well captured by current genome-wide genotyping platforms might account for inter-individual differences in blood cell counts, particularly among individuals of African ancestry. Alternatively, aggregations of rare variants might cause positive GWAS signals. Using the sickle cell anemia HBB Glu6Val variant (MIM 141900) as an example, Dickson et al. recently showed that multiple rare variants can account for some of the signals reported inGWASs for common, complex traits. 11 A number of other rare genetic variants are known to contribute to familial disorders involving the number, shape, and function of blood cells, but the extent to which these rare coding variants or polymorphisms in these genes contribute to blood cell traits in the general population is unknown. Exome sequencing has recently allowed the discovery of rare variants associated with highly penetrant Mendelian disorders. 12 The application of such next-generation sequencing technologies to more complex phenotypes in large population samples is currently limited by sequencing costs as well as technical and analytical challenges. The availability of genome-wide genotype data in many large, population-based cohort studies, combined with current genome-wide imputation approaches, offers the opportunity to extend the assessment of rare coding variants discovered through exome sequencing into larger population-based samples. As proof-of-principle, we apply this imputation approach to exome sequence data generated in a subset of African American cohort participants from the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP). Using a reference panel of 761 African Americans with exome sequence data, we imputed newly identified variants into the full African American cohorts comprising more than 13,000 individuals with blood cell phenotypes and genome-wide SNP genotyping data from four population-based studies. This allowed us to assess whether lower-frequency variants not well captured on current GWAS platforms are associated with blood cell traits in individuals of African ancestry and to identify potential genomic loci that might contribute to our understanding of hematopoiesis and blood cell biology.
Subjects and Methods

Subjects
Participants included a total of 15,829 self-identified African Americans with GWAS data from four population-based cohorts. Of these individuals, 761 had undergone whole-exome sequencing as part of the first phase of the NHLBI ESP. Detailed descriptions of each cohort are provided below. Clinical information was collected by self report and in-person examination. All participants provided written informed consent as approved by local human-subjects committees. We excluded study participants on the basis of pregnancy, cancer, or AIDS diagnosis at the time of the blood count.
Women's Health Initiative (WHI)
WHI is one of the largest (n ¼ 161,808) studies of women's health ever undertaken in the U.S. There are two major components of WHI: (1) a clinical trial (CT) that enrolled and randomized 68,132 women ages 50-79 into at least one of three placebocontrol clinical trials (hormone therapy, dietary modification, and supplementation with calcium and vitamin D); and (2) an observational study (OS) that enrolled 93,676 women of the same age range into a parallel prospective cohort study. 13 A diverse population including 26,045 (17%) women from minority groups was recruited from 1993-1998 at 40 clinical centers across the U.S. Of the CT and OS minority participants enrolled in WHI, 12,157 (including 8,515 self-identified African American and 3,642 selfidentified Hispanic subjects) who had consented to genetic research were eligible for the WHI-SHARe GWAS project. Of these eligible individuals, 8,095 African Americans were included in the current study.
Atherosclerosis Risk in Communities Study (ARIC)
The ARIC study is a prospective population-based study of atherosclerosis and cardiovascular diseases in 15,792 men and women, including 11,478 non-Hispanic whites and 4,314 African Americans drawn from four U.S. communities (suburban Minneapolis, Minnesota; Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi). 14 Only self-reported African American participants are included in this analysis. Participants were between ages 45 and 64 years at their baseline examination in 1987-1989, when blood was drawn for DNA extraction and participants consented to genetic testing. Blood for complete blood-count analysis was drawn at the baseline exam. After the availability of adequate amounts of high-quality DNA was taken into account and appropriate informed-consent and genotyping quality-control and assurance procedures were put in place, genome-wide genotype data were available for 2,989 African Americans, of whom 2,779 were included in the current analysis.
Coronary Artery Risk Development in Young Adults (CARDIA)
The CARDIA study is a prospective, multi-center investigation of the natural history and etiology of cardiovascular disease in a cohort of African Americans and whites who were 18-30 years of age at the time of initial examination. 15 The CARDIA sample was recruited at random during 1985-1986 primarily from populations based in Birmingham, Alabama; Chicago, Illinois; and Minneapolis, Minnesota; and Oakland, California from the membership of the Kaiser-Permanente Health Plan. The initial examination included 5,115 participants selectively recruited to represent proportionate racial, gender, age, and education groups from each of the four communities. From the time of initiation of the study in 1985-1986 (baseline examination), six follow-up examinations were conducted 2, 5, 7, 10, 15, 20, and 25 years later. DNA extraction for genetic studies was performed at the 10 year examination. After the availability of adequate amounts of highquality DNA was taken into account and appropriate informedconsent and genotyping quality-control and assurance procedures were put in place, genome-wide genotype data were available for 955 African Americans, of whom 953 were included in the current analysis.
Jackson Heart Study (JHS)
The Jackson Heart Study (JHS) is a prospective population-based study aimed at identifying the reasons for the high prevalence of common complex diseases among African Americans in the Jackson, Mississippi metropolitan area. Such diseases include cardiovascular disease, type-2 diabetes, obesity, chronic kidney disease, and stroke. 16 During the baseline examination period (2000-2004), 5,301 self-identified African Americans were recruited from four sources, including (1) randomly sampled households from a commercial listing; (2) ARIC participants; (3) a structured volunteer sample that was designed to mirror the eligible population; and (4) a nested family cohort. Unrelated participants were between 35 and 84 years old, and members of the family cohort were R 21 years old when consent for genetic testing was obtained and blood was drawn for DNA extraction. On the basis of DNA availability, appropriate informed consent, and genotyping results that met quality-control procedures, genome-wide genotype data were available for 3,030 individuals, including 885 who are also ARIC participants. In the current study, JHS participants who were also enrolled in the ARIC study were analyzed with the ARIC data set-for this reason, the JHS data set analyzed here is defined as 2,145 individuals, of whom 2,132 are included in the current analysis.
Blood Cell Phenotype Data
Samples for complete blood count (CBC) analysis were collected at baseline by venipuncture into tubes containing ethylenediaminetetraaetic acid (EDTA). CBCs were performed at local clinical laboratories with automated hematology cell counters and standardized quality-assurance procedures. 17 Hematocrit was reported as a percentage, and hemoglobin was reported as g/dl. WBC and platelet count were reported in millions of cells per ml. 21 This process allowed us to perform multi-sample calling of variants across thousands of samples. In brief, the distribution of observed bases and quality scores at each location (conditional on the true genotype) was modeled according to the MAQ model. 22 Using maximum likelihood, we then estimated an allele frequency for each site under the assumption that genotypes were segregating in Hardy-Weinberg proportions. For the initial variant calls, we assumed that the prior probability that a site was polymorphic was 0.0091, corresponding to an estimate of the prior for a segregating site in a simple population-genetics model and an estimated per-sample, per-base-pair heterozygosity of q ¼ 0.001. We assumed that transition and transversion mutations were equally likely, thereby allowing the use of transition-transversion (T i /T v ) ratio as a diagnostic of SNP call quality. Genotypes for each site and corresponding posterior probabilities were then calculated with the Bayes theorem, for which the Hardy-Weinberg proportions were used as priors and the MAQ error model was used for describing the conditional probability of bases and quality scores given the true genotype. After these initial SNV calls were generated, we re-examined the BAM files to collect additional information about each variant site. Filters considered the total read depth, the number of individuals with coverage at the site, the fraction of variant reads in each heterozygote, the ratio of forward and reverse strand reads carrying reference and variant alleles, and the average position of variant alleles along a read. All individual exome-sequencing data were evaluated against the QC metrics of both bulk and per-sample properties, including the distribution of novel and known variants relative to dbSNP, fingerprint concordance, Ti/Tv ratio, Het/Hom ratio, library complexity, capture efficiency and uniformity, and coverage distribution (90% at R 83 was required for completion at the University of Washington; 70% at > 203 was required for completion at the Broad Institute).
Variant data for each sample were formatted (variant call format [VCF]) as ''raw'' calls for all samples. The final SNP call set included variants that were called with posterior probability >99% (glfMultiples SNP quality >20), that were >5bp away from an indel detected in the 1000 Genomes Pilot Project, that were covered by at least one read in 85% of samples, and that had total depth across samples of between 2,500 and 2,500,000 reads (~1-100 reads per sample). Sites for which >65% of reads were heterozygotes carrying the variant allele or where the absolute squared correlation between allele (variant or reference) and strand (forward or reverse) was >0.15 were excluded.
Principal-component analysis was implemented in EIGEN-STRAT 24 within each African American cohort on cleaned genome-wide-association (GWA) genotype data. DNA samples with a genome-wide genotyping success rate of <90%, duplicate discordance or sex mismatch, genetic ancestry outliers (as determined by cluster analysis performed via principal-component analysis), SNPs with a genotyping success rate of <95%, monomorphic SNPs, SNPs with minor-allele frequency (MAF) <1%, and SNPs that mapped to several genomic locations were removed from the analyses. A total of 838,337 Affy6.0 SNPs were used for genotype imputation, as described below.
Imputation of ''Virtual Exomes'' and QC
We used the 761 African American ESP participants as a reference sample to impute variants identified by exome sequencing into the larger target sample of 15,829 African Americans with GWAS data from WHI, ARIC, CARDIA, and JHS. Specifically, we constructed, by using MaCH 1.0.18, 25 an internal reference of 1,522
phased haplotypes from the 761 African Americans with both whole-exome sequencing and Affymetrix 6.0 genotyping data. We also prephased the remaining ARIC, CARDIA, JHS, and WHI participants with genotyping data only. We then used minimac 26 to impute genotypes at markers discovered in ESP for the 15,829 African Americans. Minimac is a low-memory, computationally efficient implementation of the MaCH algorithm 25 for genotype imputation and is designed to work on phased genotypes. It can handle very large reference panels with hundreds or thousands of haplotypes. After careful QC and marker and strand matching, we imputed 420,876 markers from 838,337 markers on Affymetrix 6.0. Given the size of the reference panel, variants with MAF <0.1% were further excluded from association analyses, leaving 368,093 exome-sequencing-identified variants of MAF 0.1% or greater. Prior to data analysis, SNPs were additionally excluded if imputation quality metrics (Rsq, which is equivalent to the squared correlation between proximal imputed and genotyped SNPs) were less than the MAF-based thresholds chosen such that within each MAF category, SNPs passing the QC threshold had an average Rsq of 0.8 or more. After exclusion based on MAF and imputation quality scores, 178,954 imputed exome variants remained in the data set for association analysis. For postimputation QC, we evaluated imputation quality by two methods:
(1) comparing experimental genotypes from the Metabochip in a subset of 1,830 among the 8,059 WHI individuals; 27 and (2) imputing the 761 reference individuals one at a time: this involves masking genotypes at the exome SNPs for one reference individual at a time, imputing the masked genotypes by using the remaining 1,520 haplotypes, and comparing the imputed with the masked experimental genotypes. The two evaluation methods resulted similar conclusions, confirming that using an average Rsq of R 0.8 is an effective postimputation filter for rare variants.
Statistical Analysis
Association analyses for quantitative blood cell traits were performed separately for the WHI and CARe cohorts (ARIC, CARDIA, and JHS) via linear regression as implemented in MACH2QTL v. 1.08. Allelic dosage at each SNP (a value between 0.0 and 2.0, calculated on the basis of the probability of each of the three possible genotypes) was used as the independent variable, adjusted for primary covariates of age, sex, cohort, and global ancestry, as represented by principal-component analysis of the GWA data. All WBC traits were natural-log-transformed so that the distributions of the phenotypic data would be normalized.
The WBC analysis was additionally adjusted for genotype at rs2814778, the African-specific DARC or Duffy blood group null variant rs2814778, which is known to account for 15%-20% of the WBC variance among African Americans.
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For each blood cell phenotype, WHI and ARIC, CARDIA, and JHS study-level regression results were combined via inverse-variance weighted fixed-effects meta-analysis to derive an overall p value and effect estimate for each SNP. Meta-analyses were implemented with the METAL 28 software and corrected for genomic inflation factors (l). Between-study heterogeneity of results was assessed with Cochran's Q statistic and the I 2 inconsistency metric.
Because genome-wide association testing was performed for more than 1 million genotyped and imputed SNPs, we used a significance threshold of a ¼ 2.5 3 10 À8 , which has been suggested for African-ancestry populations so that an overall type 1 error rate of 5% can be maintained. We did not additionally correct for testing four phenotypes.
To detect transitions in ancestry along the genome, we used a Hidden Markov Model and local haplotype structure to estimate locus-specific ancestry (probabilities of whether an individual has 0, 1, or 2 alleles of African ancestry) at the LCT gene locus for each participant. 29, 30 54 raised a concern that existing approaches (such as principal-component adjustment) might not adequately control for population stratification in rare-variant association studies. In such a situation, any rare variants that have higher frequencies within a sharply defined geographic region will appear to be associated with the phenotype. To formally test this possibility, we performed genome-wide association testing in which we treated carrier status at LCT rs35940156 as the ''disease phenotype'' or dependent variable in a regression model; variants that were enriched among carriers of rs35940156 were expected to show small p values. Specifically, we defined a quantitative phenotype by the number of minor alleles at LCT s35940156. We then performed genome-wide association analysis by adjusting for principal components and used METAL to combine the results from the CARe and WHI-SHARe cohorts. As references, we selected 58 control SNPs, which we selected to have the same minor-allele frequencies as rs35940156 in the 1000 Genomes CEU and YRI populations (~2.2% in YRI, 2% in the ESP-sequenced individuals, and 0% in CEU) and repeated the genome-wide scan for the phenotype or population stratum defined at each of these control SNPs. To eliminate linkage disequilibrium (LD) at linked regions, we removed variants residing on the same chromosomes as the respective control SNPs.
Results
We performed an exome-wide analysis of four hematologic traits (hemoglobin, hematocrit, WBC, and platelet count) in African Americans from four population-based cohorts (ARIC, CARDIA, JHS, and WHI). The characteristics of each cohort are summarized in Table 1 . We imputed SNPs that we had identified by sequencing 761 African Americans from the NHLBI GO ESP to the full population-based sample of 13,959 African Americans. We used Affymetrix 6.0 genotype and blood-cell-count data for hemoglobin, hematocrit, WBC, and platelet-count phenotypes.
In contrast to conventional genome-wide SNP analyses, the variants interrogated in the current study were enriched in coding regions and had lower MAFs, and they included 178,954 high-quality, exome-sequencing-identified variants with a MAF of 0.1% or more. Of these 178,954 variants, 104,386 are present in dbSNP (build 131) and 1000 Genomes, 13,219 are in dbSNP only, and 19,979 are in 1000 Genomes only. Thus, 41,370, or 23%, of the imputed variants are ''novel.'' The distribution of the 178,954 high-quality imputed exome variants by functional category is shown in Table S1 in the Supplemental Data available with this article online. The average depth of coverage for the 100,902 high-quality variants located within exons was 101.05. The average coverage depth for the 78,052 high-quality variants located outside exons was 61.89. Of the nonexonic variants, 94.4% were located within 50 bp of an exon, and the median distance from an exon was 22 bp.
Because lower-frequency variants are more challenging for imputation, we have applied more stringent postimputation quality filtering by using higher Rsq thresholds for rarer variants. Specifically, we chose an Rsq threshold of 0.9, 0.8, 0.6, 0.3, and 0.3 for SNPs with MAF 0.1%-0.5%, 0.5%-1%, 1%-3%, 3%-5%, and >5%, respectively. Under these criteria, 92.9% of SNPs with MAF > 5% passed QC, whereas only 7.3% of SNPs with MAF ¼ 0.1%-0.5% passed QC (Table 2) . By comparing imputed genotypes with experimental genotypes from the Metabochip, 27 we estimated that the information content retained (measured by dosage r 2 , squared Pearson correlation between imputed and experimental genotypes) is > 81% across the MAF categories (Table 2) . To further evaluate the sensitivity of our imputation, we examined the coverage of coding SNPs found on the Illumina Exome-Chip; 30.6% of the coding variants on the Exome-Chip were covered by the raw imputed data, whereas 15.4% were covered by the imputed data that passed QC. These results met our expectations given that the imputation reference panel (761 African Americans) was less than 1/3 the size of the African American sample that was used in the design of the Exome-Chip array.
The genomic-control-corrected QQ plot for hemoglobin, WBC, and platelet count are shown in Figure S1 , and the corresponding Manhattan plots are shown in Figure S2 . Several regions reached genome-wide significance at the threshold of p < 2.5 3 10 À8 (Table 3) , as described in further detail below. GWAS findings for common variants derived from conventional genotyping arrays such as Affymetrix 6.0 and HapMap imputation have been reported in African Americans for WBC, 6 platelet count, 10 and hemoglobin and hematocrit. 8 Therefore, only loci newly identified through exome imputation are highlighted here.
Hemoglobin and Hematocrit
Globin Gene Variants are Significantly Associated with Hemoglobin and Hematocrit
The known rs334 sickle cell b-globin p.Glu6Val variant of HBB (MIM 141900) (MAF ¼ 0.05), which is not covered by conventional GWA panels, was significantly associated with lower hematocrit (p ¼ 5.7 3 10 À11 ) and hemoglobin (p ¼ 9.7 3 10 À6 ). Ten SNPs located on the terminal portion of the long arm of chromosome 16 near the a-globin locus were significantly associated with hemoglobin (Table 3 ; see also Table S3 ). The SNP most strongly associated with hemoglobin was rs9924561 (MAF ¼ 0.07), located in the next-to-last intron of ITFG3 (p ¼ 6.6 3 10 À24 )
( Figure 1A (Tables S2 and S4 ). Within ABO (MIM 110300) on chromosome 9, several common coding SNPs that tag the B blood group antigen (such SNPs include rs8176746, which confers a p.Met266Leu substitution in exon 7) were associated with higher hemoglobin in African Americans. The association between SNPs tagging the B blood group antigen and higher hemoglobin was recently reported in a Japanese GWAS. 4 A common rs3772219 missense variant (c.1021T>G [p.Leu341Val]; RefSeq NM_001128616.1) of ARHGEF3 (MIM 612115), which encodes rho guanine-nucleotide exchange factor 3 (RhoGEF3), was associated with higher hematocrit. A distinct set of intronic ARHGEF3 polymorphisms (tagged by rs12485738) has been associated with platelet count and mean platelet volume in European Americans, 9, 55 and the ARHGEF3 gene product was recently shown to be involved in iron uptake by erythroid cells. 
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Ancestry-Adjusted Analyses of LCT-Containing Chromosomal Region 2q21
Because ethnic background is a major determinant of WBC, careful assessment of population stratification is warranted by the presence of complex patterns of genetic variation on chromosomal region 2q21, which has undergone strong recent selective pressure in Europeans and Africans. 57 As expected, global African ancestry was strongly associated with lower WBC. In contrast, local African ancestry in the LCT region showed a weaker, but statistically significant, association with higher WBC (p ¼ 0.001). We repeated the LCT missense SNP-WBC association analyses in the 8,095 WHI participants and adjusted for global ancestry, the first ten principal components derived from GWAS data, or local ancestry, as well as for four U.S. geographic regions (Table S6 ). The associations between WBC and the rare missense LCT variants were robust to all of these covariate adjustments, as well as to adjustment for ethnicity-specific LCT promoter SNPs (rs4988235, rs3806502, rs3087343, and rs749017) that have been associated with the lactasepersistence phenotype (MIM 223100). 57 54 . In such a situation, any rare variants that have higher frequencies in this geographic region will appear to be associated with the phenotype. If this were the case, we would expect additional (noncausal) rare variants to show similar geographic clustering; in other words, we would expect an excess of unlinked rare variants showing strong LD with the LCT missense variants. When we compared the LCT missense variant rs35940156 to 58 control SNPs selected on the basis of their having the same minor-allele frequencies as rs35940156 in the 1000 Genome's CEU and YRI populations, we found no evidence that it was associated with an excess of unlinked markers across the genome. The p value distribution when rs35940156 was used as the stratum definition is not significantly different from the distribution when the control SNPs defined the stratum ( Figure S3 ). The lower extremes of the p value distributions for association with unlinked markers are also indistinguishable between the LCT and the control SNPs; for example, the 0.01% quantile ranges from 4. (
. Analysis of the LCT missense SNPs in the three cohorts (ARIC, CARDIA, JHS) with data available on WBC subtypes (n ¼ 5,105) showed the associations with neutrophil and monocyte counts were strongest (Table S7) . Using HapMap and 1000 Genomes YRI data for further examination of the LCT region revealed extensive LD between the WBC-associated missense variants and numerous other SNPs in the chromosomal region 2q21. Interestingly, the extended region of LD spans~1 Mb in Africans and includes CXCR4 (MIM 162643), which encodes a leukocyte chemokine receptor involved in hematopoietic stem cell migration and leukocyte recruitment. 58 To further assess the functional significance of the LCT variants associated with WBC (particularly whether these SNPs have any regulatory effect on expression of CXCR4), we queried these SNPs and correlated proxies (r 2 > 0.8) against a database of >30 gene eQTL data sets, as well as RNA-sequencing eQTLs and SCAN. No significant cis-eQTLs were identified with the LCT missense variants or their correlated proxies. In summary, we have identified an association between a low-frequency African-ancestry-specific missense variant of LCT and higher WBC, but the biologic mechanism underlying this genetic association requires further study.
Platelet Count Association of African-Specific MPL Lys39Asn Missense Variant with Higher Platelet Count
The strongest association signal for platelet count was rs17292650 (MAF ¼ 0.04, p ¼ 1.5 3 10 À11 ). This
African-ancestry-specific missense variant (c.117G>T [p.Lys39Asn]; RefSeq NM_005373.2) is located in exon 2 of MPL (MIM 159530), which encodes the thrombopoietin receptor on platelets and megakaryocytes (Table 3 , Figure 1C ). The c.117G>T [p.Lys39Asn] MPL variant has not been identified in prior GWASs, although it was previously discovered through a candidate-gene sequencing study of African Americans with essential thrombocytosis. 59 In a subset of 1,872 WHI African American participants who underwent genotyping of rs17292650, we confirmed that the minor allele of c.117G>T was associated with a 25. 
Additional Suggestive Loci for Platelet Count
Variants within CD109 (MIM 608859), CD36 (MIM 173510), and ITGB3 (MIM 173470), which encode several platelet surface glycoproteins involved in platelet adhesion and aggregation as well as platelet alloantigen formation, had p values for association with platelet count in the range of 10 À5 -10 À7 . (Table S8 ) GWAS recently showed that rs17154155, a common intronic variant of CD36, is associated with higher platelet count in African Americans. 10 In Figure 1D ). In conditional regression analyses, the platelet-count associations for these three CD36 variants (intronic, nonsense, and frameshift) all appeared to be conditionally independent of one another (Table S9) .
Discussion
We performed exome sequencing in a reference panel of 761 African Americans and imputed these samples into a much larger target sample of more than 13,000 from the original African American cohorts. We confirmed the association of a lower-frequency MPL receptor missense variant, c.117G>T (p.Lys39Asn), with higher platelet count in African Americans. We also identified a genomewide association between two low-frequency LCT nonsynonymous coding variants (c.301A>G [p.Ser101Gly] and c.1318G>A [p.Val440Ile]) and higher WBC in African Americans. Lastly, we identified associations of lowfrequency coding variants at existing blood-cell-associated genetic loci: MPL c.754T>C (p.Tyr252His) was associated with higher platelet count; CD36 c.975T>G (p.Tyr325*) was associated with lower platelet count; and several missense variants at the a-globin locus were associated with lower hemoglobin. Together, these results demonstrate the utility of an ''exome imputation'' approach for identifying low-frequency coding variants associated with complex blood cell phenotypes in large populationbased samples. The implications of these findings for particular blood cell phenotypes and related disorders are discussed below.
Red Blood Cell Disorders
Using a cardiovascular gene-based-tag SNP genotyping array in the population-based CARe consortium (which includes the cohorts JHS, ARIC, and CARDIA), Lo et al. reported a common variant that was located within the a-globin locus on chromosomal region 16p13 (LUC7L rs1211375) and was associated with lower hemoglobin, mean corpuscular hemoglobin, and mean corpuscular volume in African Americans. 8 This SNP might tag an African a-globin copy-number polymorphism (CNVR6569) that is absent in Europeans, 8 consistent with the known worldwide distribution of a-thalassemia copy-number variants. 60 We find evidence for additional genetic complexity and allelic heterogeneity at the a-globin locus at chromosomeal region 16p13 in African Americans; such evidence includes the association of hemoglobin with rs13335497 (c.423G>A, p.Ser141 ¼), a common synonymous variant of ITFG3, which encodes integrin-a FG-GAP repeat-containing-3. The function of the ITFG3 gene product is unknown, although it is expressed in an erythroleukemia cell line and other common polymorphisms of this gene have been associated with red blood cell indices in European and Japanese GWASs. Thus, it is possible that the independent single-nucleotide variants associated with lower hemoglobin at the a-globin locus in our data set in fact capture these different structural variants. Alternatively, one or more of these single nucleotide variants could directly disrupt normal a-globin gene expression, as has been previously reported. 64 Establishing whether any of these African American hemoglobin-associated singlenucleotide variants are themselves "causal" or are proxies for additional a-thalassemia-related copy-number variants will require additional functional and population-genetics study.
WBC
The WBC-associated LCT missense variants rs35837297 (c.301A>G; p.Ser101Gly) and rs35940156 (c.1318G>A; p.Val440Ile) are distinct from the cluster of functional promoter variants that cause lactase persistence. The lactase-persistence SNPs are located~14 kb upstream of LCT and have arisen on different population-specific haplotype backgrounds (À13910T in Europeans and À13907G, À13915G, and À14010C in East Africans) through convergent evolution as a result of positive selection. 57, 65 The WBC association we observed for the lowfrequency LCT coding variants was robust to adjustment of the European lactase-persistence variant À13910T, whereas the major East African lactase-persistence variant À14010C is absent in Nigerian Yoruba and African Americans. Hence, the observed WBC association at the LCT missense variants is unlikely to be due to population structure related to natural selection of the lactase-persistence phenotype. The WBC association observed for the lowfrequency LCT coding variants was also robust to adjustment for genome-wide, locus-specific ancestry, as well as leading principal components. The LCT-WBC association was present only among African Americans who carried two African chromosomes in the LCT genomic region, further reducing the likelihood of confounding due to continental ancestry or gross-scale geographic structure. Finally, we found no evidence suggesting that the association was due to confounding of a small and undetected population stratum, as stipulated by a model in Mathieson and McVean. 54 The mechanisms behind the association of LCT variants with higher WBC are not known. We reviewed the Mouse Phenome Database 66 and found Lct expression in the mouse is associated with CD8 count, suggesting a link to intestinal immunity and an effect of dietary exposure to lactose. It is possible that the WBC-associated LCT coding variants are proxies for a regulatory variant that controls expression or function of the nearby gene, CXCR4. Alternatively, it is possible that there exist functional CXCR4 coding variant(s) that are in LD with the LCT missense variants and that these causal CXCR4 variant(s) were not captured (or failed QC) during the original exomesequencing study. Rare activating mutations in CXCR4 are associated with WHIM syndrome (MIM 193670), a congenital immunodeficiency disorder characterized by infections and severe leukopenia. 67 From an evolutionary standpoint, the complex haplotype pattern and extensive LD in the LCT-CXCR4 region among African populations suggests the possibility that additional selective sweeps might have occurred within Africa for reasons unrelated to milk consumption, perhaps due to host interactions between blood cells and pathogens. 57 Common variants of two other chemokine-related genes, DARC (MIM 613665) and CXCL2 (MIM 139110), are associated with WBC. 5, 6 Both the DARC null variant and low WBC are highly prevalent in Africa, where the DARC variant confers resistance to malarial infection (MIM 611162).
Platelet Count
Through a candidate-gene sequencing study, the Africanspecific MPL c.117G>T (p.Lys39Asn) variant was associated with reduced platelet protein MPL expression and mild thromobocytosis in heterozygotes and with more severe thrombocytosis in homozygotes. 59 We observed a similar allele-dose-dependent effect on platelet count in African Americans. The MPL c.117G>T (p. Lys39Asn) platelet-count association was not detected previously through European or African American GWASs 9,10 because the variant is low frequency, specific to African populations, and not well tagged on the Affy6.0 platform (''tagr 2 '' ¼ 0.076). In a recent small study of 245 black South Africans, the MPL c.117G>T (p.Lys39Asn) variant was nominally associated with platelet count (p ¼ 1.6 3 10 À5 ), thus confirming the association in an independent African-ancestry sample. 68 MPL is the platelet and megakaryocyte receptor for thrombopoietin, or TPO (MIM 600044), an essential regulator of megakaryocyte differentiation and platelet production. Primary thrombocytosis, defined as a platelet count >400 3 10 9 /liter, can be due to rare MPL activating muta- 71, 72 In the case of MPL c.117G>T (p.Lys39Asn), the mechanism relating reduced MPL receptor expression to higher platelet count might seem paradoxical. Reduced amounts of platelet MPL might shift the normal negative-feedback loop between circulating platelet count and thrombopoietin levels to higher TPO and increased platelet production. 73, 74 In the current Large sample sizes will be required for robustly associating most rare coding variants with complex traits. Power calculations are shown for each variant in Tables S2, S4 , S5, and S8. Even with an effective sample size of~13,000, power to detect an association with platelet count is onlỹ 10% for the functional variants ITGB3 rs61736876 (c.557C>T [p.Pro186Leu]; MAF 0.007) and CD36 rs3211862 (c.158_159insG [p.Asn53Lysfs*4]; MAF 0.02), and the effect size is in the range of~15,000 platelets/ul (equivalent to approximately 0.25 SD unit). Therefore, even larger African American samples may be required for confirmation of associations that did not meet the threshold of genome-wide significance in the current study.
As the cost of whole-genome sequencing continues to decline, it might soon become feasible to directly genotype rare variants across the genome in tens of thousands of samples. However, because the vast majority of the variants captured through sequencing are exceedingly rare and outside the protein-coding region, it is not clear how such data would be analyzed for associations with complex traits. For variants of intermediate frequency (e.g., 0.1% < MAF < 5%), we have shown that high-coverage sequencing for variant discovery followed by imputation into large GWAS cohorts is a successful and cost-effective approach for testing associations with complex traits. An alternative approach involves a combination of lowcoverage exome sequencing in all samples and imputation with 1000 Genomes Project reference panels. 80, 81 Similar to our approach, low-coverage exome sequencing combined with 1000 Genomes imputation has the capability to capture common and intermediate frequency variation (1%-5% MAF) with increased power and cost efficiency in comparison to conventional GWAS. 80 Nonetheless, researchers
have not yet used the low-coverage sequencing approach to discover associations with complex traits, and our high-coverage sequencing approach might capture additional imputable lower-frequency coding variants (in the range of 0.1% to 1% MAF) that would not be discovered through low-coverage exome sequencing. Moreover, because many rare variants are population specific, imputation reference panels derived from the same target population might be important for detecting lowerfrequency alleles and might be less vulnerable to population stratification. By sequencing the entire exomes or protein-coding regions of the genome in well-phenotyped populationbased samples, the NHLBI GO Exome Sequencing Project has provided a large exome data set for identifying rare coding variation underlying a variety of complex traits related to heart, lung, and blood diseases. The ability to impute low-frequency coding variants with reasonable accuracy into larger data sets enables the inclusion of a greater number of causal coding-sequence variants that would otherwise not be captured by standard GWASs. Exome imputation should permit increased power to detect associations with low-frequency variants, greater characterization of allelic heterogeneity at previously known susceptibility loci, and fine mapping of causal variants. 82 Perhaps not surprisingly, all of the newly identified coding variants explain <0.5% of the variance for any given trait. For example, the LCT missense variant(s) explain only 0.2% of WBC variance. Therefore, these rare coding variants do not appear to contribute substantively to overall heritability, which has been estimated in the range of 50% for most blood cell traits. 6, 83 In prior published GWASs of blood cell traits in individuals of European descent, the proportion of variance explained by common SNPs has been~1% for hemoglobin and hematocrit, 2 5% for platelet count, 9 and~7% for WBC, 5 whereas the DARC null variant explains~15%-20% of the WBC variance in African Americans. 1, 6 Therefore, by comparison, the newly identified low-frequency coding variants explain a very small proportion of variance for each of the traits examined. Nonetheless, the evidence we found for allelic heterogeneity at several GWAS loci would not have been apparent without extending these analyses to include rare coding variants. Further studies involving larger samples will be required if we are to assess in a more comprehensive manner the hypothesis set forth by Dickson et al., 11 who suggested that multiple rare variants account for some of the signals for common, complex traits reported in GWASs. In summary, imputation of lower-frequency coding variants identified by whole-exome sequencing into large, population-based cohorts via population-specific reference panels offers the opportunity to identify variants that are associated with complex traits such as blood cell counts but that have not been previously targeted by genomewide genotyping arrays. Studying the genetics of these quantitative blood traits in diverse populations might reveal new biologic pathways that ultimately not only contribute to our understanding of hematopoiesis but also increase our understanding of the association of blood counts with cardiovascular, inflammatory, and other systemic diseases.
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